Yan Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan Mao has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Jinhua He
Xinjiang Institute of Materia Medica, Urumqi, Xinjiang, 830010, China
3 shared publications - Zhengyi Gu
Xinjiang Institute of Materia Medica, Key Laboratory of Xinjiang Uygur Medicine, Urumqi 830010, China; School of Pharmacy, Xinjiang Medical University, Urumqi 830011, China
3 shared publications - Changhong Wang
State Key Laboratory of Discovery and Utilization of Functional Components of Traditional Chinese Medicine; Key Laboratory for Standardization of Chinese Medicines, Ministry of Education; Shanghai Key Laboratory for Compound Chinese Medicines; Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China
2 shared publications - Kefeng Zhai
School of Biological and Food Engineering, Engineering Research Center for Development and High Value Utilization of Genuine Medicinal Materials in North Anhui Province, Suzhou University, Suzhou, Anhui, 234000, China
2 shared publications - Maojie Zhou
School of Pharmacy, Xinjiang Medical University, Urumqi 830011, China
2 shared publications Mireyi Bahatijiang
State Key Laboratory of Discovery and Utilization of Functional Components of Traditional Chinese Medicine; Key Laboratory for Standardization of Chinese Medicines, Ministry of Education; Shanghai Key Laboratory for Compound Chinese Medicines; Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China
2 shared publications
Latest Publications
- 19 December 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 271, 117320
Systemic exposure characteristics and pharmacokinetic studies of intranasally delivered qinhao nasal drops by UHPLC-Q/TOF-MS and UHPLC-MS/MS
- 19 December 2025
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 271, 117320
Systemic exposure characteristics and pharmacokinetic studies of intranasally delivered qinhao nasal drops by UHPLC-Q/TOF-MS and UHPLC-MS/MS
- 9 December 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 358, 121028
Dual targeting by Artemisia rupestris L. disrupting TLR4/NF-κB signaling and macrophage driven immune evasion in hepatocellular carcinoma
- 9 December 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 358, 121028
Dual targeting by Artemisia rupestris L. disrupting TLR4/NF-κB signaling and macrophage driven immune evasion in hepatocellular carcinoma
- 12 December 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 322, 117572
Exploring the molecular mechanism of Artemisia rupestris L. for the treatment of hepatocellular carcinoma via PI3K/AKT pathway
- 12 December 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 322, 117572
Exploring the molecular mechanism of Artemisia rupestris L. for the treatment of hepatocellular carcinoma via PI3K/AKT pathway
- Open Access
- 29 November 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-13
Network Pharmacology-Based Analysis of the Underlying Mechanism of Hyssopus cuspidatus Boriss. for Antiasthma: A Characteristic Medicinal Material in Xinjiang
Background. Hyssopus cuspidatus Boriss. (Shen Xiang Cao (SXC)), a traditional medicine herb in Xinjiang, has a long history of being used by minorities to treat asthma. However, its active antiasthmatic compounds and underlying mechanism of action are still unknown. The aim of this study was to investigate the bioactive compounds and explore the molecular mechanism of SCX in the treatment of asthma using network pharmacology. Methods. The compounds of SCX were collected by a literature search, and Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and SwissTargetPrediction were used to predict targets and screen active compounds. Moreover, asthma-related targets were obtained based on DisGeNET, Herb, and GeneCards databases, and a protein-protein interaction (PPI) network was built by the STRING database. Furthermore, the topological analysis of the PPI and SXC-compound-target networks were analyzed and established by Cytoscape software. Finally, the RStudio software package was used for carrying out Gene Ontology (GO) function enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. AutoDock tools and AutoDock Vina were used to molecularly dock the active compounds and key targets. Results. A total of 8 active compounds and 258 potential targets related to SXC were predicted, and PPI network screened out key targets, including IL-6, JUN, TNF, IL10, and CXCL8. GO enrichment analysis involved cell responses to reactive oxygen species, oxidative stress, chemical stress, etc. In addition, KEGG pathway analysis showed that SXC effectively treated asthma through regulation of mitogen-activated protein kinases (MAPK) signaling pathways, interleukin 17 (IL-17) signaling pathways, toll-like receptor (TLR) signaling pathways, and tumor necrosis factor (TNF) signaling pathways. Conclusion. The preliminary study that was based on multiple compounds, multiple targets, and multiple pathways provides a scientific basis for further elucidating the molecules involved and the underlying antiasthma-related mechanisms of SXC.
- 29 November 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-13
Open AccessNetwork Pharmacology-Based Analysis of the Underlying Mechanism of Hyssopus cuspidatus Boriss. for Antiasthma: A Characteristic Medicinal Material in Xinjiang
Background. Hyssopus cuspidatus Boriss. (Shen Xiang Cao (SXC)), a traditional medicine herb in Xinjiang, has a long history of being used by minorities to treat asthma. However, its active antiasthmatic compounds and underlying mechanism of action are still unknown. The aim of this study was to investigate the bioactive compounds and explore the molecular mechanism of SCX in the treatment of asthma using network pharmacology. Methods. The compounds of SCX were collected by a literature search, and Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and SwissTargetPrediction were used to predict targets and screen active compounds. Moreover, asthma-related targets were obtained based on DisGeNET, Herb, and GeneCards databases, and a protein-protein interaction (PPI) network was built by the STRING database. Furthermore, the topological analysis of the PPI and SXC-compound-target networks were analyzed and established by Cytoscape software. Finally, the RStudio software package was used for carrying out Gene Ontology (GO) function enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. AutoDock tools and AutoDock Vina were used to molecularly dock the active compounds and key targets. Results. A total of 8 active compounds and 258 potential targets related to SXC were predicted, and PPI network screened out key targets, including IL-6, JUN, TNF, IL10, and CXCL8. GO enrichment analysis involved cell responses to reactive oxygen species, oxidative stress, chemical stress, etc. In addition, KEGG pathway analysis showed that SXC effectively treated asthma through regulation of mitogen-activated protein kinases (MAPK) signaling pathways, interleukin 17 (IL-17) signaling pathways, toll-like receptor (TLR) signaling pathways, and tumor necrosis factor (TNF) signaling pathways. Conclusion. The preliminary study that was based on multiple compounds, multiple targets, and multiple pathways provides a scientific basis for further elucidating the molecules involved and the underlying antiasthma-related mechanisms of SXC.